GlassScriptPhysician profile
Eric Daniel French
NPI 1184007098
$9,870.70
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $2,079 · 2023: $6,509 · 2024: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $1,247.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $7,053.31 | 2022-2023 | Brainsway Deep Tms |
| Abbvie INC. | $1,101.59 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.62 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $169.99 | 2021-2022 | |
| Tris Pharma INC | $159.86 | 2022-2023 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.43 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $147.36 | 2021-2024 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $141.06 | 2022-2024 | Onfi, Rexulti |
| Alkermes, INC. | $124.26 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $108.19 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $104.47 | 2022-2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $98.22 | 2021-2022 | |
| Corium, LLC | $60.38 | 2023-2024 | Azstarys |
| Almatica Pharma LLC | $60.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $58.38 | 2023 | Spravato |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $39.60 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $21.29 | 2023 | Auvelity |
| Eisai INC. | $14.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric French listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.